Skip to main content

Codexis, Inc. (CDXS)

NASDAQ: CDXS · IEX Real-Time Price · USD
34.26 0.35 (1.03%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap2.22B
Revenue (ttm)101.29M
Net Income (ttm)-15.01M
Shares Out64.88M
EPS (ttm)-0.24
PE Ration/a
Forward PE138.89
Dividendn/a
Ex-Dividend Daten/a
Volume516,903
Open33.63
Previous Close33.91
Day's Range33.14 - 35.20
52-Week Range16.55 - 42.01
Beta1.59
AnalystsStrong Buy
Price Target39.38 (+14.9%)
Earnings DateNov 4, 2021

About CDXS

Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherape...

IndustryLife Sciences Tools & Services
IPO DateApr 22, 2010
Employees181
Stock ExchangeNASDAQ
Ticker SymbolCDXS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for Codexis stock is "Strong Buy." The 12-month stock price forecast is 39.38, which is an increase of 14.94% from the latest price.

Price Target
$39.38
(14.94% upside)
Analyst Consensus: Strong Buy

News

Codexis to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will ...

2 weeks ago - GlobeNewsWire

Codexis Reports Third Quarter 2021 Financial Results

Record Quarterly Total Revenue, Product Revenue and Product Gross Margin Reiterating Total Revenue Guidance of $98-103M; Raising Product Revenue Guidance to $63-66M

1 month ago - GlobeNewsWire

Will Codexis (CDXS) Report Negative Earnings Next Week? What You Should Know

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Codexis to Report Third Quarter 2021 Financial Results on November 4

REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report i...

1 month ago - GlobeNewsWire

Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?

Codexis is leveraging its core technology to create more effective life science tools.

1 month ago - The Motley Fool

Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API f...

REDWOOD CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party collaboration ...

1 month ago - GlobeNewsWire

Here's What Could Help Codexis (CDXS) Maintain Its Recent Price Strength

If you are looking for stocks that are well positioned to maintain their recent uptrend, Codexis (CDXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Str...

1 month ago - Zacks Investment Research

Codexis (CDXS) Surges 12.4%: Is This an Indication of Further Gains?

Codexis (CDXS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th...

2 months ago - Zacks Investment Research

Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin

Codexis Inc (NASDAQ: CDXS) has amended and extended its agreement with Merck & Co Inc (NYSE: MRK) to license and supply a proprietary enzyme used to manufacture sitagliptin. Sitagliptin is an active pha...

Other symbols:MRK
2 months ago - Benzinga

Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin

REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extensi...

2 months ago - GlobeNewsWire

Codexis Confirms Receipt of Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Co...

Orders Support Company's Recently Increased 2021 Guidance Orders Support Company's Recently Increased 2021 Guidance

3 months ago - GlobeNewsWire

After Golden Cross, Codexis (CDXS)'s Technical Outlook is Bright

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

3 months ago - Zacks Investment Research

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 58.82% and 41.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-La...

REDWOOD CITY, Calif. and KALAMAZOO, Mich., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc...

4 months ago - GlobeNewsWire

Codexis Announces Completion of CodeEvolver® License Technology Transfer with Global Pharmaceutical Leader

REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the Code...

4 months ago - GlobeNewsWire

ARK Investment Leans Into Biotech and Telecom Holdings

Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.

Other symbols:IRDMSURF
4 months ago - GuruFocus

Codexis Earns Milestone Payment from GlaxoSmithKline

REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant mi...

5 months ago - GlobeNewsWire

Strength Seen in Codexis (CDXS): Can Its 12.6% Jump Turn into More Strength?

Codexis (CDXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

5 months ago - Zacks Investment Research

Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product

Codexis Inc (NASDAQ: CDXS) raised its guidance for 2021 following the receipt of a binding purchase order for up to $13.9 million of a proprietary high-performance enzyme product from an undisclosed pha...

5 months ago - Benzinga

Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product

REDWOOD CITY, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021, fo...

5 months ago - GlobeNewsWire

Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fou...

REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, today announced the expansion of its strategic coll...

5 months ago - GlobeNewsWire

Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 30.00% and 21.09%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Codexis Reports First Quarter 2021 Financial Results

Total Revenue up 23% and Product Revenue Doubles Year over Year

7 months ago - GlobeNewsWire

Codexis to Report First Quarter 2021 Financial Results on May 6

REDWOOD CITY, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarte...

7 months ago - GlobeNewsWire

Codexis Getting Closer To Key Technical Benchmark

A Relative Strength Rating upgrade for Codexis shows improving technical performance. Will it continue?

8 months ago - Investors Business Daily